When comparing GLP-1 receptor agonists available in the UK, semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia) each demonstrate different nausea profiles based on clinical trial evidence and real-world data
Treating obesity through diet and exercise is linked with better outcomes, at least according to a study published in 2012 in the British Medical Journal
PubMed , The American Journal of Medicine , vol
It is designed specifically for people on Mounjaro or Wegovy and is available free to try for 7 days on iOS and Android.
Heres what the research and my clinical experience reveal: Semaglutide is a well-established option with: Weekly injections Proven safety profile Average weight loss of 15-20% of body weight Effective appetite suppression Improvements in cardiovascular health markers Tirzepatide offers: Weekly injections Potentially greater weight loss (16-22.5% of body weight) Dual-action mechanism Similar side effect profile to semaglutide Enhanced metabolic benefits In a recent head-to-head trial , tirzepatide demonstrated superior weight loss compared to semaglutide, with participants losing an average of 20.2% versus 13.7% of their body weight at 72 weeks
Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries